Clinical Trial: A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170592) titled 'A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients' on July 30.

Brief Summary: This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Treatment-Refractory Solid Tumors

Intervention: DRUG: OTS-412

3x10E8 pfu, once q3 weeks, 3 cycles, IT

DRUG: Hydroxyurea (HU)

15 mg/kg/day, 14 days, 1 cycle, PO

DRUG: Atezolizumab

1,200 mg...